Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent (Q77134015)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9714301%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

title

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9714301%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

1 reference

K S Bauer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9714301%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

S C Dixon

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9714301%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

W D Figg

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9714301%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

language of work or name

English

0 references

publication date

1 June 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9714301%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

published in

Biochemical Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9714301%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

volume

55

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9714301%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9714301%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

page(s)

1827-1834

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9714301%20AND%20SRC:MED&resulttype=core&format=json

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

3 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900046-X

Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900046-X

Thalidomide is an inhibitor of angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900046-X

Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900046-X

Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900046-X

Purification and characterization of hepatic microsomal cytochrome P-450.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900046-X

Automated high-performance liquid chromatographic assay for the determination of 7-ethoxycoumarin and umbelliferone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900046-X

Recombinant human erythropoietin stimulates angiogenesis in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900046-X

Are keratin proteins a better tumor marker than epithelial membrane antigen? A comparative immunohistochemical study of various paraffin-embedded neoplasms using monoclonal and polyclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900046-X

Angiogenesis in cancer, vascular, rheumatoid and other disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900046-X

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900046-X

The enantiomers of the teratogenic thalidomide analogue EM 12: 1. Chiral inversion and plasma pharmacokinetics in the marmoset monkey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900046-X

Determination of the thalidomide analogues 2-(2,6-dioxopiperidine-3-yl)phthalimidine (EM 12), 2-(2,6-dioxopiperidine-4-yl)phthalimidine (EM 16) and their metabolites in biological samples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900046-X

Determination of thalidomide and its major metabolites by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900046-X

Thalidomide for the treatment of chronic graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900046-X

Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900046-X

10.1016/S0006-2952(98)00046-X

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9714301%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

1 reference